Klotho vs NAD+
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Klotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profileNAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential to cellular metabolism, DNA repair, and mitochondrial function. Levels decline with age. Research focuses on restoring NAD+ through precursors (NMN, NR) or direct IV/subcutaneous administration to support longevity and energy metabolism.
Full profile| Klotho | NAD+ | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain | Nicotinamide Adenine Dinucleotide, NAD, NAD+ precursor |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) | 250mg–1000mg mg, daily (oral precursors) or weekly/monthly (IV/SubQ) |
| Administration | Intravenous (research), Subcutaneous injection | Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal |
| Key side effects | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration | Flushing (especially IV), Chest tightness during rapid IV infusion, Nausea, Fatigue (transient, day of infusion) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Klotho is research-stage, while NAD+ is preclinical only.
- Administration: Klotho — Intravenous (research), Subcutaneous injection; NAD+ — Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal.
- Dosing units differ: Klotho is dosed in mcg/kg, NAD+ in mg — they operate at different scales.
- Frequency: Klotho is typically every 3–7 days IV or SC (research); NAD+ is daily (oral precursors) or weekly/monthly (IV/SubQ).
How each works
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
NAD+
NAD+ is required for over 500 enzymatic reactions including those catalyzed by sirtuins (longevity-associated proteins) and PARPs (DNA repair enzymes). Rodent studies consistently show that restoring NAD+ levels reverses aspects of metabolic aging. Human trials with NAD+ precursors (NMN, NR) show improved muscle function, insulin sensitivity, and mitochondrial capacity in older adults.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.